On­colyt­ic virus start­up Ca­li­di se­cures $25M to­ward Se­ries B round

Ca­li­di Bio­ther­a­peu­tics, a San Diego biotech work­ing on de­vel­op­ing al­lo­gene­ic cell de­liv­ery of on­colyt­ic virus­es, said Fri­day that in­vestors have com­mit­ted $25 mil­lion to a Se­ries B round.

The press re­lease says that the fund­ing is led by At­lanta in­vest­ment firm Jack­son In­vest­ment Group, which con­tributed an ini­tial $5 mil­lion. An ad­di­tion­al group of new and pre­vi­ous in­vestors called Ca­li­di Cure, led by Ca­li­di CEO Al­lan Ca­maisa, al­so par­tic­i­pat­ed in the round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER